Portuguese American scientist Dr. Ronald A. DePinho, MD, 56, was chosen as the sole finalist to succeed John Mendelsohn as the next president of the M.D. Anderson Cancer Center, at the University of Texas in Houston.
The son of Portuguese immigrants, Dr. DePinho is a Harvard University cancer geneticist, the director of the Belfer Institute or Applied Cancer Science at the Dana-Farber Cancer Institute in Boston, and a professor of medicine and genetics at Harvard Medical School.
Internationally renowned, Dr. DePinho specializes in molecular and biological processes behind the development of cancer, aging and degenerative diseases. He is known for his research on how genes control cancer and for reversing aging in mice.
Dr. DePinho received his MD with distinction from Albert Einstein Medical College in 1981. He later completed his research training at Columbia Presbyterian Hospital.
Recent awards include the Albert Szent-Gyrgyi Prize for Progress in Cancer Research, 2009; Helsinki Medal, 2007; Albert Einstein College of Medicine Distinguished Alumnus Award, 2004; American Cancer Society Edith A. Pistorino Research Professorship, 2004; Member, Institute of Medicine of the National Academies, 2004; AACR-G.H.A. Clowes Memorial Award, 2003; American Society for Clinical Investigation Award, 2002; American Society for Clinical Investigation Award, 2000.